Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 known ✓ | P22460 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.68 |
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | GRM8 | O00222 | 1/20 | 0.38 |
| ▸ | GRM6 | O15303 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21331609 | 1.00 | EPHX1 (0.68) | EPHX1TRPM8TRPA1SLC1A2SLC1A1 | |
| SCHEMBL10001722 | 0.98 | EPHX1 (0.70) | EPHX1TRPM8TRPA1SLC1A2SLC1A1 | |
| SCHEMBL6128484 | 0.98 | EPHX1 (0.70) | EPHX1TRPM8TRPA1SLC1A2SLC1A1 | |
| SCHEMBL3958542 | 0.98 | EPHX1 (0.70) | EPHX1TRPM8TRPA1SLC1A2SLC1A1 | |
| SCHEMBL464850 | 0.98 | EPHX1 (0.70) | EPHX1TRPM8TRPA1SLC1A2SLC1A1 | |
| SCHEMBL10034575 | 0.98 | EPHX1 (0.70) | EPHX1TRPM8TRPA1SLC1A2SLC1A1 | |
| SCHEMBL12381602 | 0.98 | EPHX1 (0.70) | EPHX1TRPM8TRPA1SLC1A2SLC1A1 | |
| SCHEMBL2637678 | 0.98 | EPHX1 (0.70) | EPHX1TRPM8TRPA1SLC1A2SLC1A1 | |
| SCHEMBL1150651 | 0.98 | EPHX1 (0.70) | EPHX1TRPM8TRPA1SLC1A2SLC1A1 | |
| SCHEMBL3958539 | 0.98 | EPHX1 (0.70) | EPHX1TRPM8TRPA1SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664261-B2 | Organic compounds having cooling properties | GIVAUDAN S.A. (CH) | 2014-03-04 | — | — | US | disclosed |
| US-8487130-B2 | Menthylcarboxamides and their use as cooling agents | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2178836-B1 | AMIDE ADDITION REACTION | GIVAUDAN SA (CH) | 2013-04-17 | — | — | EP | disclosed |
| US-8377422-B2 | Carboxamide derivatives having cooling properties | GIVAUDAN S.A. (CH) | 2013-02-19 | — | — | US | disclosed |
| US-20120095042-A1 | Organic Compounds Having Cooling Properties | GIVAUDAN SA (CH) | 2012-04-19 | — | — | US | disclosed |
| EP-2427170-A2 | ORGANIC COMPOUNDS HAVING COOLING PROPERTIES | Givaudan SA (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20110195032-A1 | Menthylcarboxamides and Their Use as Cooling Agents | KAZIMIERSKI ARKADIUSZ | 2011-08-11 | — | — | US | disclosed |
| US-20110182833-A1 | Carboxamide Derivatives Having Cooling Properties | GIVAUDAN SA (CH) | 2011-07-28 | — | — | US | disclosed |
| US-7880011-B2 | reacting p-menthanecarboxamide in toluene with 2-vinyl pyridine, 18-crown-6 chelating agent , potassium tert-butoxide (20% in tetrahydrofuran), heating to produce N-(2-pyridin-2-ylethyl)p-menthanecarboxamide[(1R,2S,5R)-2-isopropyl-5-methyl-N-(2-(pyridin-2-yl)ethyl)cyclohexanecarboxamide | Givandan, S.A. (CH) | 2011-02-01 | — | — | US | disclosed |
| WO-2010128026-A2 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2010-11-11 | — | — | WO | disclosed |
| EP-2229352-A2 | CARBOXAMIDE DERIVATIVES HAVING COOLING PROPERTIES | Givaudan SA (CH) | 2010-09-22 | — | — | EP | disclosed |
| EP-2178836-A1 | AMIDE ADDITION REACTION | Givaudan SA (CH) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009070910-A2 | CARBOXAMIDE DERIVATIEVES HAVING COOLING PROPERTIES | GIVAUDAN SA (CH) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009012609-A1 | AMIDE ADDITION REACTION | GIVAUDAN SA (CH) | 2009-01-29 | — | — | WO | disclosed |
| US-20090030042-A1 | Amide Addition Reaction | GIVAUDAN, SA. (CH) | 2009-01-29 | — | — | US | disclosed |
| WO-2007138031-A2 | MENTHANE CARBOXYLIC ACID N-(ALKYLTHIOALKYL)AMIDES AND USE THEREOF AS PHYSIOLOGICALLY ACTIVE COOLING ACTIVE INGREDIENTS | SYMRISE GMBH & CO. KG (DE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030042-A1 | Amide Addition Reaction | HRH2, OGDH, MDH2 | KCNA5 2688/4885EPHX1 757/4885TRPM8 4278/4885 |
| US-20110195032-A1 | Menthylcarboxamides and Their Use as Cooling Agents | GMDS, CHIA, RIMKLA | KCNA5 2319/4885EPHX1 1156/4885TRPM8 59/4885 |
| US-20110182833-A1 | Carboxamide Derivatives Having Cooling Properties | CPS1, NQO2, NDUFA2 | KCNA5 581/4885EPHX1 3112/4885TRPM8 376/4885 |
| US-20120095042-A1 | Organic Compounds Having Cooling Properties | ME3, ME2, MSMO1 | KCNA5 2345/4885EPHX1 1320/4885TRPM8 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.